Immunome (NASDAQ:IMNM) Now Covered by Analysts at Alliance Global Partners

Alliance Global Partners began coverage on shares of Immunome (NASDAQ:IMNM) in a research note released on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $32.00 target price on the stock.

A number of other equities analysts have also recently commented on IMNM. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Immunome in a research report on Thursday, September 10th. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Truist Financial raised their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Barclays assumed coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.18.

Immunome Stock Up 4.6%

NASDAQ:IMNM opened at $25.07 on Monday. Immunome has a 12-month low of $9.36 and a 12-month high of $30.06. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of -9.91 and a beta of 2.13. The stock’s 50 day moving average price is $25.38 and its two-hundred day moving average price is $22.81.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities research analysts expect that Immunome will post -2.38 EPS for the current year.

Insiders Place Their Bets

In related news, Director Isaac Barchas sold 101,050 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00. Following the completion of the sale, the director directly owned 308,504 shares in the company, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the completion of the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. This trade represents a 77.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 635,510 shares of company stock worth $14,915,990 in the last quarter. Corporate insiders own 7.21% of the company’s stock.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Immunome during the 2nd quarter worth $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Immunome during the second quarter worth about $576,000. Readystate Asset Management LP lifted its position in Immunome by 23.3% during the second quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock worth $34,027,000 after purchasing an additional 303,958 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in Immunome during the second quarter worth about $552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Immunome by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock worth $3,997,000 after buying an additional 1,625 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.